Airway Management Tubes Market

Executive Summary

Airway Management Tubes Market was valued at US $2.02 billion in 2021 and is projected to grow at 6.41% CAGR over the forecast period to reach US $2.94 billion by 2027. Airway Management Tubes Market represented US $0.24 billion opportunity over 2019-2021 and estimated to create US $0.91 billion opportunity in 2027 over 2021.

Airway Management Tubes from Consainsights analyses the Airway Management Tubes Market in the Life Sciences industry over the forecast period to 2027.

Airway Management Tubes research report from Consainsights outlines the detailed strategic analysis, trends, market opportunities, growth prospects, industry and market challenges and sustainable solutions to sustain in the competitive environment.

Airway Management Tubes segmentation includes Device Type, End Users and Geography.

Based on the Device Type, the Airway Management Tubes analysis covers Supraglottic Devices, Infraglottic Devices, Resuscitators, Laryngoscopes, Other Devices.

In Device Type segment, Infraglottic Devices segment has highest cagr growth of 5.68%.

Based on the End Users, the Airway Management Tubes analysis covers Hospitals, Clinics, Ambulatory Surgical Centers.

In End Users segment, Ambulatory Surgical Centers segment has highest cagr growth of 5.68%.

Based on the region, the Airway Management Tubes analysis covers North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America.

Key companies operating in the market include Medtronic Plc, Becton, Dickinson & Company, Smiths Medical, Inc., Teleflex, Fisher & Paykel Healthcare, Cook Medical, Tracoe Medical, ConvaTec, Pulmodyne, Inc., Fuji System Corporation and so on. This report covers the detailed analysis of the company profiles such as business segments, product portfolio, key brand insights and growth strategies adopted, company SWOT and Strategy analysis along with the financial analysis and analyst insights on the key companies operating in this market.

Market Overview

Definition & Scope

The base currency considered was the US Dollar (USD). Conversion of other currencies to USD was considered on the basis of the average exchange rate for the respective review-period years. The exchange rate conversion for forecast period was determined according to the base year’s conversion rates.

The base year was identified based on the availability of annual reports and secondary information. The base year considered for this study is 2027.

The review period considered for this study is from 2018-2027. The CAGR is for the forecast period, 2022-2027.

Market size estimations for the forecast years were in real terms. Inflation is not part of the pricing, and the average selling price (ASP) was kept constant throughout the forecast period for each country.

Distribution of primary interviews conducted was based on the regional share of the market and the presence of key players in each region.

As a result of data triangulation through multiple methodologies and approaches, the weighted averages of resulting estimates were considered to be the final values.

Currency, Year & Forecast

The currency used in this report is USD, with the market size indicated in terms of USD million/billion.

For companies reporting their revenues in USD, the revenues were taken from their respective annual reports/SEC filings.

For companies reporting their revenues in other currencies, the average annual currency conversion rates were used for a particular year to convert the value to USD Market Definition.

Device Type

Introduction

In 2021, Supraglottic Devices segment has the highest revenue of US $0.76 billion and is expected to grow at CAGR of 5.68% by 2027 Infraglottic Devices segment has highest cagr growth of 5.68%.

Supraglottic Devices

Supraglottic Devices segment was valued at US $0.67 billion in 2019 and is projected to grow at 5.68% CAGR over the forecast period to reach US $1.11 billion by 2027. Supraglottic Devices segment represented US $0.09 billion opportunity over 2019-2021 and estimated to create US $0.35 billion opportunity in 2027 over 2021.

Infraglottic Devices

Infraglottic Devices segment was valued at US $0.36 billion in 2019 and is projected to grow at 5.68% CAGR over the forecast period to reach US $0.60 billion by 2027. Infraglottic Devices segment represented US $0.05 billion opportunity over 2019-2021 and estimated to create US $0.19 billion opportunity in 2027 over 2021.

Resuscitators

Resuscitators segment was valued at US $0.34 billion in 2019 and is projected to grow at 5.68% CAGR over the forecast period to reach US $0.56 billion by 2027. Resuscitators segment represented US $0.05 billion opportunity over 2019-2021 and estimated to create US $0.17 billion opportunity in 2027 over 2021.

Laryngoscopes

Laryngoscopes segment was valued at US $0.26 billion in 2019 and is projected to grow at 5.68% CAGR over the forecast period to reach US $0.42 billion by 2027. Laryngoscopes segment represented US $0.03 billion opportunity over 2019-2021 and estimated to create US $0.13 billion opportunity in 2027 over 2021.

Other Devices

Other Devices segment was valued at US $0.15 billion in 2019 and is projected to grow at 5.68% CAGR over the forecast period to reach US $0.24 billion by 2027. Other Devices segment represented US $0.02 billion opportunity over 2019-2021 and estimated to create US $0.08 billion opportunity in 2027 over 2021.

End Users

Introduction

In 2021, Clinics segment has the highest revenue of US $1.00 billion and is expected to grow at CAGR of 5.68% by 2027 Ambulatory Surgical Centers segment has highest cagr growth of 5.68%.

Hospitals

Hospitals segment was valued at US $0.83 billion in 2019 and is projected to grow at 5.68% CAGR over the forecast period to reach US $1.37 billion by 2027. Hospitals segment represented US $0.11 billion opportunity over 2019-2021 and estimated to create US $0.43 billion opportunity in 2027 over 2021.

Clinics

Clinics segment was valued at US $0.88 billion in 2019 and is projected to grow at 5.68% CAGR over the forecast period to reach US $1.45 billion by 2027. Clinics segment represented US $0.12 billion opportunity over 2019-2021 and estimated to create US $0.45 billion opportunity in 2027 over 2021.

Ambulatory Surgical Centers

Ambulatory Surgical Centers segment was valued at US $0.07 billion in 2019 and is projected to grow at 5.68% CAGR over the forecast period to reach US $0.12 billion by 2027. Ambulatory Surgical Centers segment represented US $0.01 billion opportunity over 2019-2021 and estimated to create US $0.04 billion opportunity in 2027 over 2021.